Loading
companiesCompany
Surgimab
Surgimab is a French company whose fluorescent antibody SGM-101 lights up carcinoembryonic antigen so surgeons can see colorectal and pancreatic tumours in the operating theatre.
Also called: SurgiMab SAS
Overview
Surgimab develops SGM-101, a chimeric antibody against carcinoembryonic antigen (CEA) conjugated to a near-infrared fluorophore for fluorescence-guided surgery. Injected a few days before the operation, it marks CEA-expressing tumour deposits so surgeons can find peritoneal metastases, small liver lesions and positive margins. Phase 2 studies in colorectal and pancreatic cancer showed changed surgical plans in a substantial share of patients, and a phase 3 trial in colorectal cancer has completed.
Headquarters
Montpellier, FR
Scorecard
All companies#318of 1244 companies, score 13
- phase 3 +3
- targets +2
- modalities +2
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 1 targets, 8 registry studies. Formula on the scorecards page.
Type
Website
Phase 3monoclonal antibody
SGM-101 is an experimental monoclonal antibody from Surgimab in phase 3 trials for colorectal cancer, aimed at CEACAM5.
drugs
Phase 3monoclonal antibody